KIT and leukemia: In healthy samples (compared to AML patients’ samples), we found significantly higher frequencies of Tem/eff/CD3+ and Tem/effCD4−/TCD4− after MLCWB-DC(Kit M) (%Tem/eff/CD3+: healthy: 62 ± 26; leukemia: 43 ± 19; p = 0.03 and %Tem/effCD4−/TCD4−: healthy: 60 ± 23; leukemia: 40 ± 19; p = 0.02) (Figure 2).